Assessing Bioequivalence of Generic Antiepilepsy Drugs
Ann Neurol 70:221-228,192, Krauss, G.L.,et al, 2011
Generic Substitution in the Treatment of Epilepsy: Case Evidence of Breakthrough Seizures
Neurol 71:525-530, Berg,M.J.,et al., 2008
Lower Phenytoin Serum Levels in Persons Switched from Brand to Generic Phenytoin
Neurol 63:1494-1496, Burkhardt,R.T.,et al, 2004
Effect of Food on Absorption of Dilantin Kapseals and Mylan Extended Phenytoin Sodium Capsules
Neurol 57 582-589,571, Wilder,B.J.,et al, 2001
Therapeutic Bioequivalency Study of Brand Name Versus Generic Carbamazepine
Neurol 42:1147-1153, Oles,K.S.,et al, 1992
Generic Substitutions for Antiepileptic Drugs
Neurol 40:1647-1651, Nuwer,M.R.,et al, 1990
Switching the Manufacturer of Antiepileptic Drugs is Associated with Higher Risk of Seizures: A Nationwide Study of Prescription Data in Germany
Ann Neurol 84:918-925, Lang, J.D.,et al, 2018
Antiseizure Medications
Neurol 86:e187-e188, Karceski, S., 2016
Generic Anticonvulsant Use in Children: Do We Have Evidence to Recommend Brand Formulations?
Arch Neurol 66:1417-1418, Hamiwka,L., 2009
Assessment:Generic Substitution for Antiepileptic Medication
Report of Therap & Tech Assess Subcomm, Neurol 40:1641-164390., , 1990